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ABSTRACT
The purpose of this research was to prepare a dry powder
vaccine formulation containing whole inactivated influenza
virus (WIIV) and a mucoadhesive compound suitable for
nasal delivery. Powders containing WIIV and either lactose
or trehalose were produced by lyophilization. A micro-ball
mill was used to reduce the lyophilized cake to sizes suit-
able for nasal delivery. Chitosan flakes were reduced in size
using a cryo-milling technique. Milled powders were sieved
between 45 and 125 μm aggregate sizes and characterized
for particle size and distribution, morphology, and flow
properties. Powders were blended in the micro-ball mill
without the ball. Lyophilization followed by milling pro-
duced irregularly shaped, polydisperse particles with a me-
dian primary particle diameter of ~21 µm and a yield of
~37% of particles in the 45 to 125 µm particle size range.
Flow properties of lactose and trehalose powders after lyo-
philization followed by milling and sieving were similar.
Cryo-milling produced a small yield of particles in the de-
sired size range (G10%). Lyophilization followed by milling
and sieving produced particles suitable for nasal delivery with
different physicochemical properties as a function of process-
ing conditions and components of the formulation. Further
optimization of particle size and morphology is required for
these powders to be suitable for clinical evaluation.
KEYWORDS: Intranasal delivery, dry powder, influenza
vaccine, mucoadhesive, lyophilizationR
INTRODUCTION
Influenza is a highly contagious disease that causes high
morbidity and mortality worldwide each year. Most deaths
currently associated with influenza in industrialized coun-
tries occur among the elderly—those over 65 years of age.1
Vaccination has a major impact on preventing the epidemic
spread of the disease. The World Health Organization rec-
ommends that elderly persons, and persons of any age who
are considered to be at high risk because of underlying
health conditions, be vaccinated. Influenza vaccination can
reduce both health care costs and productivity losses asso-
ciated with influenza illness.2 Current efforts to control
influenza are based on the use of annual inactivated intra-
muscular (IM) or live attenuated, cold-adapted trivalent in-
tranasal (IN) liquid vaccines.
Recently, contamination of trivalent influenza suspensions
for IM injection resulted in a vaccine shortage. The dis-
covery of contaminated injectable doses resulted in a 48%
shortfall in the number of doses that the US federal health
agencies had planned to distribute in 2004–2005.3 This led
to the rationing of influenza vaccines, with priority given to
elderly persons, immunocompromised persons, and pro-
fessional health care workers. Steps must be taken to en-
sure that a vaccine shortage will not happen in the future.
Delivery of vaccines and therapeutic drugs to the nasal and
pulmonary systems has been studied extensively.4-8 These
approaches offer noninvasive alternatives to needle-based
delivery. IN delivery of vaccines has been shown to elicit
both mucosal and systemic immune responses.9-12 How-
ever, in most cases liquid formulations have been used. The
development of heat-stable powder vaccine formulations
and delivery technologies may help overcome the low-
temperature storage and distribution requirements associ-
ated with current vaccine delivery methods. Dry powder
formulations are potentially superior to liquid formulations
in their sterility and stability, facilitating mass vaccination
and eliminating the need for the cold chain.13-17 Few dry
powder vaccine formulations have been prepared, and the
ones that have been reported were not intended for nasal
delivery.15,16,18,19 The reasons for the limited interest in
powders are difficult to enumerate. However, the produc-
tion of powders with reproducible particle size and dis-
tribution, stability, and performance characteristics may be
a perceived barrier to development when compared with
the production of solution formulations for parenteral or
nasal administration.
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Vaccination against influenza via the IN route has drawn
considerable attention. The majority of infectious agents,
including influenza, invade the human body through mu-
cosal routes, making IN administration an attractive vac-
cination method. The ability to elicit both mucosal and
systemic immunity and the ease and safety of administra-
tion are advantages that IN delivery has over standard
parenteral delivery. FluMist (Medimmune Vaccines, Inc,
Gaithersburg, MD) elicits mucosal immunity and was shown
to be safe and well-tolerated in healthy pediatric and adult
populations.2,20,21 However, this live attenuated vaccine is
not indicated for children under age 5, elderly persons, and
immunocompromised persons.22 As has always been the
case for IM influenza vaccines, FluMist must be stored as a
frozen liquid and thawed immediately before use to main-
tain potency. In the developing world, in particular, there is
an urgent need to overcome such cold chain requirements
and to provide single-use, nonrefillable delivery technolo-
gies that require minimal training. While dry powder vac-
cines have the potential to meet requirements, there have
been very few reported studies investigating IN delivery of
dry powder vaccines. Furthermore, the powders used in
prior studies were not fully characterized, and there was no
description of a device suitable for reproducible IN powder
delivery in humans.13,14,17
In our hypothesis, we proposed that the residence time of
the dry powder vaccine on the nasal mucosa would influ-
ence the efficacy of the vaccine. Elements of this hypothesis
were addressed through the following steps: developing a
dry powder antigen preparation; processing the powder to
achieve appropriate particle size characteristics (10-50 μm);
and incorporating a mucoadhesive compound to poten-
tially enhance residence time on the nasal mucosa,23 thus
amplifying the immune response elicited. The latter bio-
logical effects are not described in this article.
A previously published study using the formulation of
antigen-excipient-mucoadhesive described in this article fo-
cused on the ability of a powder vaccine to elicit a signifi-
cant serum antibody response in rats equivalent to that of a
liquid vaccine administered via IN delivery or IM injection.24
Chitosan was employed in the formulation to potentially
increase the residence time on the nasal mucosa. When dosed
in animals, the powder vaccine described in this article gen-
erated strong nasal mucosal and systemic immune responses
using the combination of an IN delivery device and a for-
mulation of influenza vaccine. In the previously published
studies, the powder vaccine was shown to be more stable
than liquid vaccine at various temperatures and relative
humidities. IN powder with mucoadhesive generated serum
antibody titers 910 times that of IM injection, IN liquid, or
IN powder without mucoadhesive. Comparable nasal im-
munoglobulin A (IgA) titers were generated in the groups
receiving IN doses containing antigen. No nasal IgA re-
sponse was seen in animals receiving IM doses or in animals
receiving IN doses with excipients alone.
The present article is the first detailed description of the
preparation and characterization of the antigen powders
used in the subsequent in vivo studies.24
MATERIALS AND METHODS
Non-spray-dried crystalline lactose monohydrate (Mallinc-
krodt Baker, Paris, KY, referred to as lactose), D-(+)-
trehalose dihydrate (referred to as trehalose), and chitosan
(MW 50 000 to 190 000 Da, minimum 85% deacetylated)
were purchased from Sigma Chemical Co (St Louis, MO).
Whole inactivated influenza virus (WIIV) of the H1N1 strain,
A/PR/8/34, purchased from Charles River SPAFAS (North
Franklin, CT; Lot4PRI000901, 2 mg/mL), was used as a
liquid preparation as provided by the vendor or formulated as
a powder. WIIV was propagated in the allantoic fluid of
chicken eggs, purified from sucrose gradient; inactivated by
beta-propiolactone; and resuspended in HEPES saline.
Powder Preparation of Vaccine
Lyophilization
The final formulation contained 100 μg of influenza vac-
cine blended in 10 mg of lactose or trehalose. A solution
with 5 mg/mL of total solids was to be prepared. For vac-
cine antigen samples, 1 mL of vaccine suspension was thawed
and added to the disaccharide solution, stirred, and placed in
vials for freeze-drying (Kinetics Flexi-Dry, Kinetics Ther-
mal Systems, Stone Ridge, NY). The vials were frozen at –
20°C and placed on the manifold at a temperature of –55°C
and chamber pressure of 5 x 10-3mm Hg. A drying time of
48 hours was adopted following preliminary experiments
with trehalose. To minimize humidity effects, subsequent
work was completed in a dry box (G15% relative humidity).
Particle Size Reduction
A micro-ball mill (SPEX Certiprep #3117, Metuchen, NJ)
was used to reduce particle size for small quantities of pow-
der (G300 mg). The mill consists of a stainless steel vessel
containing several ¼-inch steel balls. The micro-ball mill
was sealed and mounted on an oscillating motor (Variable
Speed Jig Saw, Black and Decker Inc, Towson, MD) to pro-
vide agitation. Run parameters are shown in Tables 1 and 2.
Sieving
Milled powders were sieved (model no SS-5 sieve shaker,
Gilson Co, Worthington, OH) with 300, 125, and 45 μm
sieves. The powders were sieved for 2 hours in tap mode,
and particles in the 45 to 125 μm size range were collected.
AAPS PharmSciTech 2006; 7 (1) Article 19 (http://www.aapspharmscitech.org).
E2
Mucoadhesive Compound
Chitosan was supplied as solid flakes roughly 2 to 4 mm in
size. The flakes are not brittle at room temperature; their
flexibility reduces their susceptibility to size reduction by a
simple milling technique. Consequently, a cryo-milling tech-
nique was used. Sixty milligrams of chitosan was placed in
a vial with a single steel ball. The vial was immersed in
liquid nitrogen, left to cool for 5 minutes, and then placed
on the jigsaw for milling at 1600 rpm for 20 minutes. This
process was repeated 3 times, and the resulting powder
was then sieved as above.
Physicochemical Characterization
Particle Size Analysis
Each powder was sized by laser diffraction (Malvern 2600
Series, Worcestershire, UK) with a small liquid dispersion
sample cell. The sample cell has an integral stir bar and a
volume of ~5 mL. The cuvette was filled with 1%wt/wt Span
80 (Sigma) in light, white mineral oil (Sigma). Powder sam-
ples of ~10 mg were dispersed in 2 mL of 1% wt/wt Span
80 in the light, white mineral oil, sonicated for 5 minutes,
and then placed into the sample cell one drop at a time until a
laser obscuration between 2% and 30% was achieved (n = 3).
Results were reported as the median diameter (D50) and
the span ([D90-D10]/D50). This technique was previously
validated using light microscopy (data not shown).
Powder Morphology
The powders were adhered to double-sided adhesive car-
bon tabs (Ted Pella Inc, Redding, CA) on aluminum stubs
(Ernest F. Fullam, Inc, Latham, NY) scanning electron mi-
croscopy (SEM). A Polaron sputter coater (model E-5200,
Electron Beam Services, Agawan, MA) was used to coat
the samples with gold-palladium. A scanning electron mi-
croscope (JEOL 6300, JEOL Corp, Peabody, MA) was used
with an electron beam at an acceleration voltage of 15 kV
and a working distance of ~25 mm. For examination of the
freeze-dried cakes, samples were dusted onto a double-stick
carbon tape, then coated with platinum to ~4 nm. A scan-
ning electron microscope (LEO 1450 VP, Leo Microscopy,
Inc, Thornwood, NY) was used with an electron beam at an
acceleration voltage of 20 kV. Representative areas of the
stub were photographed.
Flow Properties
Bulk and Tapped Densities. The bulk and tapped densities
were determined for bulk powders, 45 to 125 μm size frac-
tion of unmilled powders and 45 to 125 μm size fraction
of milled powders (n = 3). Approximately 10 mL of pow-
der was measured.25 Dividing the difference between the
tapped and bulk densities by the tapped density determines
the Carr’s Compressibility Index (CCI).26
Table 1. Parameters and Particle Size and Distribution for Steel Ball Milling of Lactose Experiments (n = 3)*
Run Milling Load, mg Milling Speed, rpm Milling Time D50, μm, mean (SD) Span, mean (SD)
1 240 200 5 minutes — —
2 200 200 10 minutes — —
3† 200 200 10 minutes — —
4 200 600 5 minutes — —
5 200 600 15 minutes — —
6 100 600 20 minutes — —
7 100 200 15 minutes 30.5 (5.1) 5.20 (2.87)
8 100 200 30 minutes 22.1 (7.0) 3.43 (0.77)
9 100 200 1 hour 12.4 (1.0) 3.70 (0.48)
10 100 200 2 hours 7.5 (1.7) 3.66 (0.35)
11 150 200 30 minutes 18.3 (2.2) 2.98 (0.10)
*Particle sizing was not completed on runs with milling speeds of 600 rpm or milling loads ≥ 200 mg. SD indicates standard deviation.
†One steel ball was used as the milling media, with the exception of Run 3, in which 2 balls were used.
Table 2. Parameters and Particle Size and Distribution for Steel Ball Milling of Trehalose Experiments (n = 3)*
Run Milling Load, mg Milling Speed, rpm Milling Time D50, μm, mean (SD) Span, mean (SD)
12 100 200 15 minutes 13.2 (0.8) 2.19 (0.08)
13 100 200 30 minutes 11.3 (2.6) 2.27 (0.24)
14 100 200 1 hour 30.1 (8.0) 4.03 (1.28)
15 100 200 2 hours 12.5 (3.5) 2.34 (0.21)
16 150 200 15 minutes 23.2 (0.2) 2.04 (0.09)
17 150 200 30 minutes 21.4 (0.4) 2.14 (0.04)
*SD indicates standard deviation.
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Static Angle of Repose. Measurements of the static angle of
repose were conducted for bulk powders, 45 to 125 μm
sieved fraction of bulk powders and 45 to 125 μm sieved
fraction of milled powders (n = 3). Approximately 10 mL
of powder was measured using a funnel and a flat col-
lection surface.27
Statistical Analysis
The experimental data were analyzed by a 1-way analysis
of variance.
RESULTS AND DISCUSSION
Powder Preparation of Vaccine
Lyophilization
The freeze-dried material formed white, porous cakes show-
ing slight shrinkage, but no large-scale collapse was ob-
served. The morphology of lyophilized material was observed
using SEM (Figure 1).
Particle Size Reduction
Very little particle size reduction occurred for the larger load
(200 mg) milling runs or for runs shorter than 15 minutes
(Runs 1-5). When milled at the higher velocity (600 rpm,
Run 6), the powder was recovered in large flakes, suggest-
ing melting and recrystallization of the lactose under the
higher energy conditions. In general, trehalose powder was
reduced in size more rapidly by milling than lactose was.
Milling was most effective for a smaller load of powder.
Ball milling of powders is a common particle size reduction
method in which a powder formulation is fractured by the
repetitive collision of stainless-steel or ceramic balls or cyl-
inders (milling media). Total milling time, speed, powder
mass, size of mill, and number of milling media elements
are all important variables for milling and must be deter-
mined separately for each formulation.28 The effect of
milling speed on production of 45 to 125 μm particles may
be explained by the degree of aggregation. Faster milling
speed corresponds to faster particle size reduction. Typically,
the degree of milling reaches a plateau and then decreases
because of the creation of aggregates.28 For the effect of ball
loading, milling occurs more slowly for a higher percentage
of filling since the milling media has reduced freedom of
motion. The combined effect of milling time and powder
load also may be explained by speed of milling since a
longer mill time is required to mill a larger load of powder.
Milling methods generally result in nonspherical solid par-
ticles with a wider size distribution than in spray-drying. In
addition, frictional heating of the milling must be con-
trolled, as it can reduce the activity of the thermolabile ma-
terials such as vaccines. A slow milling speed was used to
minimize the potential for milling to reduce vaccine potency.
[Should a “Sieving” head and section appear here, as at this
point in the Materials and Methods section?]
Mucoadhesive Compound
Particle sizing by sieving of chitosan after cryo-milling in-
dicated that a very small percentage (G10%) of powder was
produced in the desired size range of 45 to 125 μm. This
sieved powder fraction was recovered for use as a blended
mucoadhesive in the vaccine-containing formulation.24
Physicochemical Characterization
Particle Size Analysis
Particle size and distribution are important factors in the
development of a dry powder nasal formulation. Particles
G10 μm have the potential to be deposited in the lower
respiratory tract if inhaled.29 This can lead to issues with
potential toxicities as well as reduce the dose fraction
reaching the intended site of delivery. Particles that are too
large and/or in too high of a mass may not dissolve ef-
ficiently on the nasal mucosa.27
Particle sizing results are shown in Tables 1 and 2. Particle
size analysis was not completed on Runs 1 to 6, as stated
above.
Lactose. One- and 2-hour mill times resulted in a large pro-
portion of particles that were potentially respirable (G10 μm)
and unsuitable for nasal delivery. The 15-minute mill time
resulted in ~35% of particles exhibiting volume diameters
between 45 and 125 μm, as did the 30-minute mill time
(Figure 2). In the case of the 15-minute mill time, a sig-
nificant proportion of particles were 9125 μm, while for
the 30-minute mill time a significant proportion of particles
were G10 μm and no particles were 9125 μm. Therefore, a
mill time between 15 and 30 minutes would maximize the
number of particles in the 45 to 125 μm size range. Al-
ternatively, a slightly larger mill loading would slow down
the milling rate so that particles in the desired size range
could be generated without a large percentage of respirable
Figure 1. Scanning electron micrographs of (a) top surface
(500×) and (b) cross-section (500×) of the lyophilized cake.
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particles. Consequently, powder loads of 150 mg were used
for subsequent lactose formulations.
Trehalose. Trehalose milled at 60 or 120 minutes tended to
form aggregates, increasing the median diameter of the
resultant powder. Increasing the powder load within the
mill from 100 to 150 mg increased the fraction of particles
in the 45 to 125 μm particle size range from 5% and 7% to
21% and 37%, for 15 and 30 minutes, respectively. These
conditions (150 mg, 200 rpm, 1 steel ball, 30-minute mill
time) maximized the production of appropriately sized par-
ticles and were chosen as the production conditions.
The span is a measure of the polydispersity of the powder.
Milling of freeze-dried cakes effectively produced particles
with sizes appropriate for nasal delivery. However, the span
of the lyophilization followed by milling (LFM) powders
indicates that a large number of fine particles are present. It
should be noted that the particle sizing of powders dis-
persed in light mineral oil with surfactant determines the
primary particle size of the powders. This includes fine
particles that are aggregated with larger particles. Further
characterization of particle size by an aerodynamic method
will be required to adequately describe the impact of these
fine particles on deposition into the lower respiratory tract.
As with other processing methods, excipient choice is cru-
cial for the optimization of the formulation. Disaccharide
sugars are commonly used in lyophilized formulations be-
cause they are effective cryoprotectants.30 Lactose and tre-
halose have been used in a variety of formulations for nasal
delivery. However, lactose is a reducing sugar that has been
shown to degrade proteins when stored as a dried solid at
room temperature.31 Trehalose, on the other hand, is not a
reducing sugar and does not cause proteins to lose activity.
Because of this, initial milling optimization was completed
with lactose, but the final formulation was optimized by
using trehalose.
Powder Morphology
Scanning electron micrographs of trehalose powder after
milling are shown in Figure 3. LFM produced polydis-
perse, irregularly shaped particles.
When delivered in vivo, the nasal IgA responses elicited by
IN powder delivery were more variable compared with
those induced by the liquid vaccine.24 This variability may
be due, in part, to the differences in particle size distribution
and morphology observed for these powders, leading to less
reproducibility in emitted dose. Additional work to optimize
the formulation is underway to address this issue. Evalua-
tion of the lyophilized cakes revealed the presence of pores
10 to 40 μm in diameter (Figure 1). These pores were pro-
duced from long channels formed by the crystallization
and removal of water. When these cakes are milled, the
particles produced are needlelike and are difficult to blend
uniformly with other excipients. Further evaluation of the
Figure 2. Particle sizing results for (a) lactose, 100 mg, 15-minute mill time (D10 = 9.9 μm, D50 = 28.0 μm, and D90 = 128.0 μm);
(b) lactose, 100 mg, 30-minute mill time (D10 = 4.7 μm, D50 = 22.2 μm, and D90 = 85.3 μm); (c) trehalose, 150 mg, 30-minute
mill time (D10 = 6.1 μm, D50 = 21.0 μm, and D90 = 50.6 μm); and (d) trehalose, 150 mg, 30-minute mill time, 45 to 125 μm sieved
fraction (D10 = 8.3 μm, D50 = 28.8 μm, and D90 = 128.0 μm).
Figure 3. Scanning electron micrographs of trehalose powder, 150 mg, 30-minute mill time.
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freeze-drying process will be required to produce a more
uniform distribution of particles by creation of a lyophilized
cake with smaller pores. In addition, alternative methods
of manufacture, such as spray-freeze-drying, might solve
the problem.
Flow Properties
The flow properties measure the cohesive forces of a
powder.25,27 In these experiments, manufacturing condi-
tions were optimized for producing particles in the desired
size range (45-125 μm), not for flow properties. However,
the flow properties do affect the performance of the final
product. The ability of a powder to flow is one of the fac-
tors that affect the mixing of different materials to form a
powder blend.25 This may be important for the blending of
the virus and excipient with the mucoadhesive compound.
Also, because nasal delivery requires a fluidization of the
powder bed, it is conceivable that flow properties of pow-
ders could affect the emitted dose from the device and
deposition in the nasal cavity.
Bulk and Tapped Densities. CCI values are reported in
Table 3. The bulk lactose, sieved bulk lactose, and both
lyophilized followed by milling and sieving (LFMS) pow-
ders had similar CCI values (P G .05). The LFMS powders
had bulk densities of ~0.07 g/mL as compared with the
bulk and sieved bulk powder, which had bulk densities of
0.4 to 0.6 g/mL. Bulk trehalose and sieved bulk trehalose
had CCI values that were significantly lower than those of
any of the other powders (P G .05).
The more compressible a powder is (ie, the higher the
CCI), the greater the cohesive forces of a powder, making it
flow poorly. A free-flowing powder has a CCI less than
~20% to 21%.26 Bulk trehalose and sieved bulk trehalose
had CCI values of ~23. However, the LFMS powder con-
taining trehalose had a CCI value of ~34. Generally, com-
pared with powders with larger particle sizes, powders with
smaller particle sizes pack better, increasing the bulk den-
sity of the powders. However, this is not the case with
trehalose. This difference can be attributed to the irregular,
needlelike shape of the particles, which leads to larger voids
in the powder. LFMS trehalose and lactose powders exhibit
needlelike morphology; bulk lactose is an elongated crystal
and therefore has a similarly high CCI value.
Static Angle of Repose. Static angles of repose of the pow-
ders are reported in Table 3. Both the bulk lactose and
the sieved bulk lactose had static angles of repose of ~49°.
The sieved bulk trehalose had the smallest angle of repose.
LFMS produced powders with similar static angles of re-
pose in each material (P 9 .05).
The greater the static angle of repose, the greater the
cohesive force of a powder. Powders with static angles of
repose less than 40° are considered to be free-flowing pow-
ders; with angles greater than 50°, the powders flow poorly
or not at all.26,28 Lactose and trehalose powders have simi-
lar flow properties after manufacture by LFMS. The smaller
particle size of the LFMS trehalose powder, when compared
with the sieved bulk trehalose powder, indicates a signifi-
cant decrease in the powder’s potential ability to flow. In the
case of lactose, the LFMS powder has particle size char-
acteristics similar to those of the sieved bulk powder, but the
static angle of repose indicates that the LFMS powder
exhibits a flow that is better than the sieved bulk powder’s.
CONCLUSIONS
Powders of different composition (lactose, trehalose, and
chitosan) prepared under a variety of processing conditions
(milling, powder quantity, and number of steel balls) ex-
hibited a range of physicochemical properties (particle size
and distribution, morphology, bulk/tapped density, and an-
gle of repose). A powder vaccine formulation suitable for
nasal delivery was obtained by lyophilization, followed by
milling and sieving under optimized conditions. Further
optimization in conjunction with the development of a de-
livery device is required for these observations to be suit-
able for clinical studies.
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Table 3. Particle Size Data and Flow Properties of Lactose and Trehalose (n = 3)*
Powder
Median Diameter,





Static Angle of Repose (°),
mean (SD)
Lactose
Bulk 25.8 (0.7) 2.64 (0.05) 29.70 (1.69) 49.0 (0.5)
Sieved bulk 18.3 (0.7) 2.59 (0.06) 33.33 (0.95) 49.5 (3.7)
Milled, sieved 15.3 (2.2) 2.90 (0.06) 29.50 (1.33) 37.3 (1.6)
Trehalose
Bulk 37.6 (0.8) 2.14 (0.07) 23.80 (1.47) 30.3 (3.6)
Sieved bulk 34.1 (0.4) 2.12 (0.04) 22.97 (1.34) 21.6 (1.5)
Milled, sieved 37.1 (4.5) 4.47 (3.36) 33.94 (3.74) 37.4 (1.7)
*SD indicates standard deviation.
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